Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 8/20 | 0.62 |
| ▸ | CES2 | O00748 | 7/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475220 | 0.93 | CES1 (0.64) | CES1CES2ALDH1A1AKR1B1FAAH | |
| SCHEMBL5514001 | 0.91 | CES2 (0.65) | CES1CES2ALDH1A1GPR84PPARG | |
| SCHEMBL6650435 | 0.84 | CES1 (0.58) | CES1CES2CA1ALDH1A1TSHR | |
| SCHEMBL4645993 | 0.80 | CAMK2A (0.42) | CES1CES2GPR84TDP1 | |
| SCHEMBL28740609 | 0.78 | CES1 (0.59) | CES1CES2CA1ALDH1A1TP53 | |
| SCHEMBL4645915 | 0.78 | CES1 (0.35) | CES1CES2FAAH | |
| SCHEMBL4647735 | 0.78 | GPR84 (0.42) | CES1CES2ALDH1A1GPR84TSHR | |
| SCHEMBL2846729 | 0.78 | CES1 (1.00) | CES1CES2CA1ALDH1A1TP53 | |
| SCHEMBL4647229 | 0.76 | CES1 (0.37) | CES1CES2FAAH | |
| SCHEMBL27620252 | 0.76 | ALDH1A1 (0.46) | CES1CES2ALDH1A1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-8129488-B2 | Transition metal complexes, catalyst compositions containing the same, and olefin polymerization using the catalyst compositions | LG CHEM, LTD. (KR) | 2012-03-06 | — | — | US | disclosed |
| US-20090209712-A1 | TRANSITION METAL COMPLEXES, CATALYST COMPOSITIONS CONTAINING THE SAME, AND OLEFIN POLYMERIZATION USING THE CATALYST COMPOSITIONS | LG CHEM., LTD. (KR) | 2009-08-20 | — | — | US | disclosed |
| US-7538239-B2 | Transition metal complexes, catalyst compositions containing the same, and olefin polymerization using the catalyst compositions | LG CHEM, LTD. (KR) | 2009-05-26 | — | — | US | disclosed |
| WO-2007007992-A1 | TRANSITION METAL COMPLEXES, CATALYST COMPOSITIONS CONTAINING THE SAME, AND OLEFIN POLYMERIZATION USING THE CATALYST COMPOSITIONS | LG CHEM, LTD. (KR) | 2007-01-18 | — | — | WO | disclosed |
| US-20070010637-A1 | Transition metal complexes, catalyst compositions containing the same, and olefin polymerization using the catalyst compositions | LG CHEM, LTD. (KR) | 2007-01-11 | — | — | US | disclosed |
| US-6603007-B1 | Intermediates in the fields of pharmaceuticals, agrichemicals, ligands, silver halide photosensitive materials, liquid crystals, surfactants, electrophotography and organic electroluminescence | SANKIO CHEMICAL CO., LTD. (JP) | 2003-08-05 | — | — | US | disclosed |
| EP-0737200-A1 | BIOLOGICALLY ACTIVE SILICON COMPOUNDS AND THEIR THERAPEUTIC AND COSMETIC APPLICATIONS | EXSYMOL (MC) | 1996-10-16 | — | — | EP | disclosed |
| WO-1996010575-A1 | BIOLOGICALLY ACTIVE SILICON COMPOUNDS AND THEIR THERAPEUTIC AND COSMETIC APPLICATIONS | EXSYMOL (MC) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | CES1 4199/4885CES2 3215/4885CA1 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.